Analyst firms · UBS · CRL

UBS CRL price target and rating history

Charles River Laboratories International Inc. (CRL) · Health Care

UBS rates Charles River Laboratories International Inc. (CRL) Buy with a $357 price target, as of its latest action on Sep 30, 2026. It has published 4 rating actions on CRL since August 2021, including 0 upgrades and 1 downgrade. Across 5 firms with a CRL price target in the last 12 months, the median target is $220. UBS's $357 is 62% above that.

Current rating

Buy

Price target

$357

Median target, all firms

$220

Actions on CRL

4

UBS price target on CRL

Every UBS rating on CRL

• Sep 30, 2026
  ResumeUBS resumes coverage at Buy, price target $357
• Jan 17, 2025
  DowngradeUBS downgrades to Neutral from Buy, price target $250 to $185
• Feb 17, 2022
  ReiterateUBS cuts its price target to $420 from $465, keeps Buy
• Aug 17, 2021
  ReiterateUBS raises its price target to $465 from $390, keeps Buy

How other firms rate CRL

Each firm's latest rating and stated target in the last 12 months.

Questions about UBS and CRL

What is UBS's price target for CRL?

UBS's latest stated price target for Charles River Laboratories International Inc. (CRL) is $357, from its action on Sep 30, 2026.

What is UBS's rating on CRL?

UBS rates CRL Buy, a bullish rating, as of Sep 30, 2026.

When did UBS last change its view on CRL?

On Sep 30, 2026, UBS resumes coverage at Buy, price target $357.

How does UBS's CRL target compare with other analysts?

Across 5 firms with a CRL price target in the last 12 months, the median target is $220. UBS's $357 is 62% above that.

More CRL rating histories

• CLSA5
• Morgan Stanley4
• BofA Securities3
• Jefferies4
• Citigroup5
• Rothschild & Co Redburn3
• Guggenheim3
• Credit Suisse3

All UBS ratingsCRL news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.